Announcements Trials
Browse Landscape

Phase

Phase 3 23Phase 2 22Phase 4 6Phase 2/3 4Phase NA 2

Status

Completed 3Terminated 2Unknown 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6Gynecologic 1

Conditions

Prostatic Neoplasms 6Neoplasms 1Metabolic Syndrome 1Hypogonadism 1Fatty Liver 1

Interventions

Zoledronic Acid 15enzalutamide 10Leuprolide 9Goserelin 8bicalutamide 7acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 6Triptorelin Pamoate 6Prednisone 6Nivolumab 6Abiraterone Acetate 6luprolide acetate gel depot 5Sunitinib 5Magnetic Resonance Spectroscopy 5Everolimus 5Dutasteride 5Specimen Handling 4Sodium Chloride 4Propofol 4Prednisolone 4Androgen Antagonists 42-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 4pazopanib 3fluciclovine F-18 3darolutamide 3cabazitaxel 3Trimethoprim, Sulfamethoxazole Drug Combination 3Rocuronium 3Mitomycin 3Midazolam 3Flutamide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 4 × Triptorelin Pamoate × Genitourinary × Clear all
NCT01673984 2025-05-23

GREAT

Ipsen

Phase 4 Terminated
27 enrolled 13 charts
Genitourinary

Prostatic Neoplasms

NCT04248621 2021-07-29

Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients

Wonju Severance Christian Hospital

Phase 4 Unknown
164 enrolled
Genitourinary

Prostatic Neoplasms

NCT01753297 2020-12-09

PRIORITI

Ipsen

Phase 4 Completed
226 enrolled 19 charts
Genitourinary

Prostatic Neoplasms

NCT02749825 2016-04-25

Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer

Pharmatech

Phase 4 Terminated
41 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT02102646 2015-10-28

MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism

Herlev Hospital

Phase 4 Completed
31 enrolled
Genitourinary

Fatty Liver, Hypogonadism, Prostatic Neoplasms, Metabolic Syndrome

NCT01161563 2013-09-06

Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

Watson Pharmaceuticals

Phase 4 Completed
118 enrolled 7 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡